NCT06562166 Online Adaptive Radiotherapy for Cervical Cancer
| NCT ID | NCT06562166 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Peking Union Medical College Hospital |
| Condition | Cervical Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 124 participants |
| Start Date | 2024-09-05 |
| Primary Completion | 2027-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 124 participants in total. It began in 2024-09-05 with a primary completion date of 2027-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the clinical efficacy and safety of online adaptive radiotherapy for cervical cancer patients received radical radiotherapy. By comparing with image-guided radiotherapy, the study explores the potential advantages of online adaptive radiotherapy in reducing treatment toxicity and improving local control.
Eligibility Criteria
Inclusion Criteria: 1. 18-80 years old; 2. Pathologically confirmed diagnosis of cervical cancer and pathological type of cervical squamous carcinoma; 3. 2018 FIGO Stage Ib3, II, IIIB and IIIC1 4. Proposed radical pelvic radiotherapy + concurrent sensitizing chemotherapy (platinum-based (cisplatin 30-40mg/m2 or carboplatin alone), starting concurrently in the first week, ≥5 courses) 5. ECOG score 0-2 6. Life expectancy greater than 6 months 7. Ability to remain lying down for more than 30 minutes 8. Patients were fully voluntary and autonomous and co-operated in signing the study informed consent form 9. Complete blood count and basal metabolic indexes within 14 days before enrolment must meet the following requirements: NEUT ≥ 1.5\*109/L, HGB ≥ 60g/L, platelets ≥ 100×109/, blood creatinine \<1.5 mg/dL. AST and ALT are within 2 times the upper limit of normal 10. Must complete baseline assessments and investigations required before treatment before enrolment 11. be eligible for regular follow-up Exclusion Criteria: 1. Have received radiotherapy or chemotherapy in the past 2. Have undergone radical surgery for cervical cancer 3. Have a previous history of malignant tumor 4. Pregnant or lactating women 5. Presence of other serious co-morbidities such as poorly controlled cardiovascular, urinary, digestive, respiratory, hematological and central nervous system diseases.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06562166 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 80 Years, studying Cervical Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06562166 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06562166 currently recruiting?
Yes, NCT06562166 is actively recruiting participants. Contact the research team at sunshuai@pumch.cn for enrollment information.
Where is the NCT06562166 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06562166 clinical trial?
NCT06562166 is sponsored by Peking Union Medical College Hospital. The trial plans to enroll 124 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.